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Abstract
Introduction Several studies have shown a correlation between
body mass index (BMI) and both the development of critical
illness and adverse outcomes in critically ill patients. The goal of
our study was to examine this relationship prospectively with
particular attention to the influence of concomitant diabetes
mellitus (DM).
Methods We analyzed data from 15,408 participants in the
Atherosclerosis Risk in Communities (ARIC) study for this
analysis. BMI and the presence of DM were defined at baseline.
We defined 'acute organ failure' as those subjects who met a
standard definition with diagnostic codes abstracted from
hospitalization records. Outcomes assessed included the
following: risk of the development of acute organ failure within
three years of the baseline examination; in-hospital death while
ill with acute organ failure; and death at three years among all
subjects and among those with acute organ failure.
Results At baseline, participants with a BMI of at least 30 were
more likely than those in lower BMI categories to have DM
(22.4% versus 7.9%, p  < 0.01). Overall, BMI was not a
significant predictor of developing acute organ failure. The risk
for developing acute organ failure was increased among
subjects with DM in comparison with those without DM (2.4%
versus 0.7%, p < 0.01). Among subjects with organ failure, both
in-hospital mortality (46.5% versus 12.2%, p < 0.01) and 3-year
mortality (51.2% versus 21.1%, p  < 0.01) was higher in
subjects with DM.
Conclusion Our findings suggest that obesity by itself is not a
significant predictor of either acute organ failure or death during
or after acute organ failure in this cohort. However, the presence
of DM, which is related to obesity, is a strong predictor of both
acute organ failure and death after acute organ failure.
Introduction
Obesity is one of the major health problems in our society and
its prevalence is rising worldwide [1,2]. Currently, about 130
million US adults, 65% of the population, are overweight or
obese. In addition, an increasing proportion of children in the
USA are either overweight or obese, and this number has
almost doubled over the past two decades [1].
Excess body weight increases the risk of hypertension, coro-
nary artery disease, stroke, sleep apnea, and certain cancers
[3-6]. Several population studies have described an associa-
tion between body mass index (BMI) and mortality as a U-
shaped curve, demonstrating increased mortality in the lowest
and highest BMI distribution, even when controlling for age,
smoking, and history of other comorbidities [7-11]. Obesity is
also strongly associated with an increased risk of diabetes
[12].
However, the influence of BMI on morbidity and mortality in
critically ill patients is still controversial [13,14]. Retrospective
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analysis of 63,646 patients from a multi-institutional intensive
care unit database showed increased mortality in underweight
patients (BMI ≤ 20) but not in overweight or obese patients
[15].
By contrast, Goulenok and colleagues demonstrated, in a pro-
spective study of critically ill patients, that a higher BMI was
associated with increased mortality [16]. The authors did not
include diabetes as an independent variable in the analysis
and could not explain the results even though the infection rate
and the duration of mechanical ventilation were not increased
in the obese group. Studies of critically ill patients who are
morbidly obese (BMI > 40) have shown more complications
and higher mortality but have not controlled for diabetes melli-
tus (DM) [17,18].
The relationship between obesity and diabetes, and particu-
larly the modifying effect of the latter, in the development of
acute organ failure, critical illness, and subsequent mortality is
not well defined. A better understanding of this relationship
may help to improve interventions and therefore outcomes in
this commonly seen group of patients.
The goals of this analysis were to examine the effect of BMI in
the development of acute organ failure and subsequent mor-
tality in a large, population-based, prospective cohort. We also
wished to determine the role of DM in modifying the effect of
obesity.
Materials and methods
Study population
The Atherosclerosis Risk in Communities (ARIC) study is a
prospective, population-based study of the natural history and
etiology of cardiovascular disease. The ARIC population is a
probability sample of 15,792 men and women aged from 44
to 66 years from four US communities (Suburban Minneapolis,
Minnesota; Washington County, Maryland; Forsyth County,
North Carolina, and Jackson, Mississippi) originally studied in
1986 to 1989 [19]. The cohort population reflects the demo-
graphic sample of the community except Jackson, where only
African-Americans were included. Participants underwent
baseline clinical examination, BMI measurement, and pulmo-
nary function testing, and provided information on their medi-
cal and smoking history and educational background. The
study was approved by institutional review boards at the clini-
cal sites, and informed consent was obtained from all
participants.
Subjects
We restricted this analysis to participants for whom there was
complete baseline data on variables important to this analysis,
including BMI, DM status, lung function testing, and smoking
history. We excluded 208 subjects for whom there were miss-
ing data on diabetes status, 131 subjects for whom there were
missing data on lung function, and 45 subjects for whom there
were missing data on other key variables, resulting in 15,408
participants in our analytic cohort.
Hospitalization summaries, including International Classifica-
tion of Disease, Ninth Revision (ICD-9) codes for the dis-
charge diagnoses and procedures performed, and disposition
were available for all study participants. In addition, data from
death certificates were also available.
Definitions of variables
Acute organ failure
We identified these subjects as those who were hospitalized
and developed acute organ dysfunction as defined by Martin
and colleagues [20] using ICD-9 codes (sepsis was not
required as part of this definition). Diagnostic codes for organ
dysfunction in these systems were included: respiratory, cardi-
ovascular, renal, hepatic, hematologic, metabolic, and neuro-
logic. Although one would assume that most inpatients who
develop 'acute organ failure' would be critically ill and admitted
to an intensive care unit, the site of in-hospital treatment was
not available in the database.
Body mass index
Weight and height were measured, and BMI, calculated as
weight (in kilograms) divided by the square of the height (in
meters) was defined at baseline. Each group was further
divided into four BMI subgroups, as follows: underweight
(defined as BMI ≤ 20 kg/m2), normal (defined as a BMI of 21
to 24 kg/m2), overweight (defined as a BMI of 25 to 29 kg/m2)
and obese (defined as BMI ≥ 30 kg/m2). These are commonly
accepted standard subgroups except that we did adjust the
underweight group, generally defined as BMI ≤ 18.5, to
increase the sample size in this group and provide more stable
estimates [1].
Diabetes status
We classified subjects as having DM at the baseline examina-
tion if they had any of the following: a positive response to the
question 'Has a doctor ever told you that you had diabetes
(sugar in the blood)?'; a report of taking medication for 'diabe-
tes or high blood sugar' in the two weeks before the survey; a
fasting blood sugar of 126 or higher. We were not able to dis-
tinguish between types 1 and 2 DM.
Lung function
We used a modification of the criteria developed by the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) [21]
to classify subjects according to their GOLD stages of chronic
obstructive pulmonary disease (COPD): GOLD stage 3 or 4
(forced expiratory volume in 1 second (FEV1)/forced vital
capacity (FVC) < 0.70 and FEV1 < 50% predicted), GOLD
stage 2 (FEV1/FVC < 0.70 and FEV1 ≥ 50 to < 80% pre-
dicted), GOLD stage 1 (FEV1/FVC < 0.70 and FEV1 ≥ 80%),
restricted (FEV1/FVC  ≥ 0.70 and FVC < 80% predicted),
GOLD stage 0 (presence of respiratory symptoms in theAvailable online http://ccforum.com/content/10/5/R137
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Table 1
Demographic distribution and outcomes of study participants
Category n (%) Acute organ failure within 3 years (%) Death within 3 years (%)
Age group
44–49 4,106 (26.7) 0.4 1.1
50–54 4,007 (26.0) 0.6 1.0
55–59 3,761 (24.4) 0.9 2.3
60–66 3,534 (22.9) 1.8 4.0
Sex
Male 6,918 (44.9) 1.1 2.7
Female 8,490 (55.1) 0.6 1.5
Race
White 11,365 (73.8) 0.9 1.6
Black 4,043 (26.2) 0.7 3.2
Smoking status
Current smoker 4,394 (28.5) 1.2 3.4
Former smoker 4,964 (32.2) 0.9 1.8
Never smoker 6,050 (39.3) 0.6 1.3
Diabetes mellitus
Yes 1,830 (11.9) 2.4 5.4
No 13,578 (88.1) 0.7 1.6
Body mass index
<20 506 (3.3) 1.4 3.0
20–24 4,610 (29.9) 0.9 2.0
25–29 6,058 (39.3) 0.8 1.9
≥30 4,234 (27.5) 0.9 2.2
Education level
<12 years 3,646 (23.7) 1.4 3.6
12 years 4,991 (32.4) 0.6 1.9
≥12 years 6,771 (43.9) 0.7 1.3
GOLD categorya
GOLD 3 or 4 280 (1.8) 5.4 8.6
GOLD 2 1,469 (9.5) 1.9 4.1
GOLD 1 1,677 (10.9) 0.9 2.0
GOLD 0 2,170 (14.1) 1.2 2.2
Restricted 1,295 (8.4) 1.4 3.9
Normal 8,517 (55.3) 0.4 1.1
Total 15,408 0.9 2.0
Data are taken from the Atherosclerosis Risk in Communities study 1986–1989 and follow-up. FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity. aModified Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 (FEV1/FVC < 0.70 and FEV1 < 50% 
predicted), GOLD stage 2 (FEV1/FVC < 0.70 and FEV1 ≥ 50 to < 80% predicted), GOLD stage 1 (FEV1/FVC < 0.70 and FEV1 ≥ 80%), restricted 
(FEV1/FVC ≥ 0.70 and FVC < 80% predicted), GOLD stage 0 (presence of respiratory symptoms in the absence of any lung function 
abnormality). All lung function measurements were pre-bronchodilator values.Critical Care    Vol 10 No 5    Slynkova et al.
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Table 2
Odds ratios, from multivariable logistic regression models, for outcomes within 3 years
Category n (%) Acute organ failure within 3 years; odds 
ratio (95% CI)b
Death within 3 years; odds ratio 
(95% CI)
Age group
44–49 4,106 (26.7) 1.0 1.0
50–54 4,007 (26.0) 1.2 (0.6–2.4) 0.9 (0.6–1.4)
55–59 3,761 (24.4) 1.6 (0.9–3.0) 1.8 (1.2–2.6)
60–66 3,534 (22.9) 2.9 (1.6–5.2) 3.0 (2.1–4.3)
Sex
Male 6,918 (44.9) 1.0 1.0
Female 8,490 (55.1) 0.6 (0.4–0.9) 0.6 (0.4–0.7)
Race
White 11,365 (73.8) 1.0 1.0
Black 4,043 (26.2) 0.7 (0.5–1.1) 2.0 (1.5–2.6)
Smoking status
Current smoker 4,394 (28.5) 1.2 (0.7–1.9) 1.8 (1.4–2.5)
Former smoker 4,964 (32.2) 1.0 (0.6–1.6) 1.1 (0.8–1.5)
Never smoker 6,050 (39.3) 1.0 1.0
Diabetes mellitus
Yes 1,830 (11.9) 3.2 (2.1–4.7) 2.7 (2.1–3.5)
No 13,578 (88.1) 1.0 1.0
Body mass index
<20 506 (3.3) 1.3 (0.6–2.8) 1.1 (0.7–2.0)
20–24 4,610 (29.9) 1.0 1.0
25–29 6,058 (39.3) 0.8 (0.5–1.2) 0.8 (0.6–1.1)
≥30 4,234 (27.5) 0.9 (0.6–1.4) 0.8 (0.6–1.1)
Education level
<12 years 3,646 (23.7) 1.3 (0.8–1.9) 1.5 (1.1–2.0)
12 years 4,991 (32.4) 0.8 (0.5–1.3) 1.4 (1.1–1.9)
≥12 years 6,771 (43.9) 1.0 1.0
GOLD categorya
GOLD 3 or 4 280 (1.8) 9.4 (4.8–18.4) 4.3 (2.6–7.0)
GOLD 2 1,469 (9.5) 3.6 (2.0–6.4) 2.2 (1.5–3.2)
GOLD 1 1,677 (10.9) 1.9 (0.98–3.6) 1.3 (0.9–1.9)
GOLD 0 2,170 (14.1) 2.8 (1.6–5.2) 2.4 (1.7–3.5)
Restricted 1,295 (8.4) 2.9 (1.7–5.0) 1.6 (1.1–2.3)
Normal 8,517 (55.3) 1.0 1.0
Data are taken from the Atherosclerosis Risk in Communities study 1986–1989 and follow-up. FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity. aModified Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 (FEV1/FVC < 0.70 and FEV1 < 50% 
predicted), GOLD stage 2 (FEV1/FVC < 0.70 and FEV1 ≥ 50 to < 80% predicted), GOLD stage 1 (FEV1/FVC < 0.70 and FEV1 ≥ 80%), restricted 
(FEV1/FVC ≥ 0.70 and FVC < 80% predicted), GOLD stage 0 (presence of respiratory symptoms in the absence of any lung function 
abnormality). All lung function measurements were pre-bronchodilator values. b95% confidence intervals (CI) that do not include 1.0 are 
significant at the p = 0.05 level.Available online http://ccforum.com/content/10/5/R137
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absence of any lung function abnormality), and no lung dis-
ease. Bronchodilator response was not evaluated in this sur-
vey, so the classification is based on the 'pre-bronchodilator'
level. We used data from asymptomatic never-smokers with no
lung disease, stratified by race and sex, to develop internal
prediction equations to determine normal values for lung
function.
Other variables
Respondents with positive responses to the questions 'Have
you ever smoked cigarettes?' and 'Do you now smoke ciga-
rettes?' were classified as 'ever smokers' and 'current smok-
ers', respectively. Education level was categorized as less than
high school, completion of high school, or more than high
school. Baseline age was grouped into four strata: 44 to 49
years, 50 to 54 years, 55 to 59 years, and 60 to 66 years.
Outcome variables
The primary outcomes of interest were the risk of the develop-
ment of acute organ failure within three years of the baseline
examination, in-hospital mortality related to any acute organ
failure during that period, and all-cause mortality at three years.
Analysis
All analyses were conducted with SAS version 8.2 (SAS Insti-
tute, Cary, NC, USA), SUDAAN version 8.0 (RTI, Research Tri-
angle Park, NC, USA) and SPSS version 10 (SPSS Inc,
Chicago, IL, USA). Multivariable logistic regression models
were developed for the outcomes of any hospitalization with
acute organ failure, death at three years, and in-hospital death
among those with acute organ failure. Models were adjusted
for age, sex, race, smoking status, education level, BMI, diabe-
tes status, and lung function status.
Cox proportional hazard regression models were developed
with the SUDAAN procedure SURVIVAL to account for differ-
ential follow-up in ARIC participants. Time of follow-up was
used as the underlying time metric. For deaths, the exit date
was the date of death reported on the death certificate and, for
survivors, the exit date was the date on which the participant
was last known to be alive. Plots of the log-log survival curves
for each covariate were used to show that the proportional-
hazards assumptions were met. Age, sex, race, smoking sta-
tus, education level, BMI, diabetes status, and lung function
status were included in the adjusted models, and the models
were evaluated for interactions.
Results
A total of 15,792 adults aged 44 to 66 years participated in
the ARIC study. We excluded 384 subjects with missing data
either on diabetes status, lung function or other key variables,
resulting in 15,408 subjects in our analytic cohort.
The demographic characteristics of the cohort population at
baseline and their outcomes are shown in Table 1. About one-
third of the study population (29.9%) had an ideal body weight
(BMI 21 to 24), 39.3% were overweight (BMI 25 to 29) and
27.5% were obese (BMI ≥ 30). This distribution reflects the
US population well, with an estimated prevalence of about
30% obese and 35% overweight [1]. The mean BMIs of the
cohort by BMI category was 18.9 (BMI < 20), 22.9 (BMI = 20
to 24), 27.3 (BMI = 25 to 29), and 34.5 (BMI ≥ 30).
Table 3
The risk of development of critical illness, in-hospital mortality and all-cause mortality at 3 years
Diabetes mellitus Number of subjects Acute organ failure 
hospitalization
Acute organ failure with in-
hospital death
Acute organ failure with all-
cause mortality at 3 years
Absent
BMI ≤ 20 484 7 (1.5) 28.6 28.6
BMI 21–24 4,383 32 (0.7) 12.5 15.6
BMI 25–29 5,424 30 (0.6) 13.3 23.3
BMI ≥ 30 3,287 21 (0.6) 4.8 23.8
Total 13,578 90 (0.7) 12.2 21.1
Present
BMI ≤ 20 22 0 NA NA
BMI 21–24 227 8 (3.5) 37.5 37.5
BMI 25–29 634 16 (2.5) 62.5 62.5
BMI ≥ 30 947 19 (2.0) 36.8 47.4
Total 1,830 43 (2.4) 46.5 51.2
Data are taken from from the Atherosclerosis Risk in Communities study 1986–1989 and follow-up, and are presented as proportions (%) over 
the 3-year study follow-up period. BMI, body mass index.Critical Care    Vol 10 No 5    Slynkova et al.
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Overall, 1,830 (11.9%) of all participants had DM. Participants
with DM were more likely than those without DM to have a BMI
of 30 or more (52% versus 24%, p < 0.01). The prevalence of
DM increased with increasing BMI: 4.4% for BMI < 20, 4.9%
for BMI = 20 to 24, 10% for BMI = 25 to 29, and 22.4% for
BMI ≥ 30. Of the 1,830 subjects classified as having DM, 636
(43%) were classified solely on the basis of a fasting blood
sugar of more than 126 mg/dl.
The development of acute organ failure among participants
with different BMI subgroups was almost identical: 0.9% of
subjects with ideal body weight developed acute organ failure,
in comparison with 0.8% and 0.9% for overweight and obese
subjects, respectively. BMI subgroups had similar mortality at
the 3-year follow-up (Table 1). Within three years 5.4% of sub-
jects with diabetes, in contrast with 1.6% of subjects without
diabetes, died (Table 1).
Risk factors for developing acute organ failure within three
years of the baseline evaluation and death within three years
are displayed in Table 2. The significant risk factors for acute
organ failure included older age, male sex, DM, and lower lev-
els of lung function. These same factors, along with smoking,
black race, and a lower educational level, predicted death
within three years. The presence of DM was among the strong-
est independent predictors for the risk of acute organ failure,
with a threefold increased risk (odds ratio 3.2; 95% confi-
dence interval 2.1 to 4.7), and for all-cause mortality at 3 years
(odds ratio 2.7; 95% confidence interval 2.1 to 3.5).
Table 3 displays the risk of the development of acute organ
failure, in-hospital mortality among those with acute organ fail-
ure, and mortality at three years among those with acute organ
failure by DM status. Subjects with DM were both more likely
to develop a organ failure (2.4% versus 0.7%, p < 0.01) and
to die during that hospitalization (46.5% versus 12.2%, p <
0.01) than were subjects without DM.
Time to the development of acute organ failure is presented in
Figure 1, stratified by BMI (Figure 1a) and by DM status (Fig-
ure 1b). Cox proportional-hazards models in Table 4 show that
in comparison with subjects without DM with BMIs of 21 to
24, subjects with DM had about a threefold higher risk of
developing acute organ failure. Although the confidence inter-
vals were wide because of sample size, a similar trend for a
higher risk of in-hospital mortality was also noted among sub-
jects with DM.
Discussion
The results of this large prospective cohort study of middle-
aged adults in the USA suggest that the development of acute
organ failure and death after acute organ failure is more related
to the presence of DM than to an increased BMI. Our definition
of acute organ failure is, we believe, a surrogate for critical ill-
ness, in that these events occurred in the setting of a hospital-
ization. Our results do not support the contention that obesity
itself is a risk factor for increased mortality in patients with
acute organ failure. It brings up a new perspective on this still
controversial subject of obesity, critical illness, and mortality. In
addition, our findings did not confirm increased mortality in
overweight or obese critically ill patients without DM.
Previous studies have shown that a low BMI is a significant
predictor of higher hospital mortality [9,11]. This increased risk
among patients with low BMIs has also been demonstrated in
critically ill patients, although these data are limited [15,22].
Our data suggested that subjects with low BMI developed
organ failure earlier (Figure 1 and Table 4) and had a higher
risk of in-hospital death, although the confidence intervals
were wide and did not reach significance.
Table 4
Results from models predicting time to acute organ failure and risk of in-hospital death
Diabetes mellitus Body mass index Time to acute organ failure, hazard 
ratio (95% CI)
Risk of in-hospital death during acute organ 
failure, odds ratio (95% CI)
No ≤20 1.5 (0.7–3.4) 2.3 (0.3–15.3)
No 21–24 1.0 1.0
No 25–29 0.7 (0.4–1.2) 0.7 (0.2–3.2)
No ≥30 0.9 (0.5–1.6) 0.2 (0.04–1.7)
Yes ≤20 NA NA
Yes 21–24 3.4 (1.6–7.4) 6.8 (1.00–45.8)
Yes 25–29 2.8 (1.5–5.1) 3.2 (0.9–11.9)
Yes ≥30 2.7 (1.5–4.9) 2.1 (0.5–8.6)
Data are taken from the Atherosclerosis Risk in Communities study 1986–1989 and follow-up. Models were adjusted for age, sex, race, smoking 
status, education level, body mass index, diabetes status, and lung function status. 95% confidence intervals (CI) that do not include 1.0 are 
significant at the p = 0.05 level. NA, not available (there were no critical illness hospitalizations in this subgroup).Available online http://ccforum.com/content/10/5/R137
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Conversely, other epidemiological studies have shown that
high BMI is associated with higher all-cause mortality rates
[8,9]. In one large prospective cohort study the mortality rate
for overweight non-smoking men was 3.9 times higher then for
non-smoking men of ideal weight [9]. Some authors have pos-
tulated that obesity may not be a risk factor with regard to sub-
sequent mortality in critically ill individuals, but rather that it
could have a beneficial role of 'nutritional reserve' in the face
of critical illness [15].
The relationship between an increased BMI and DM has been
well established [12,23,24]. Our data, similarly, showed that
subjects with BMIs ≥ 30 had a fourfold higher prevalence of
DM than subjects with BMIs of 20 to 24. Weight gain, which
frequently precedes the onset of diabetes, is also considered
to be a risk factor for this disease [25,26]. Both increased
insulin secretion and insulin resistance result from obesity, and
hyperglycemia and insulin resistance are the hallmarks of dia-
betes. Hyperglycemia has been shown to increase the release
of pro-inflammatory mediators such as IL-6, IL-8, and TNF,
which are important in inflammation [27]. In addition, high glu-
cose levels have been shown to have deleterious effects on
optimal macrophage and neutrophil function [28]. These neg-
ative effects of hyperglycemia are responsible for the
increased risk of infection, cardiovascular diseases, organ dys-
function, and certain cancers, as has been shown recently
[29-31].
Our findings suggest that DM and associated hyperglycemia
with insulin resistance, rather than obesity itself, is responsible
for the development of acute organ failure and subsequent
adverse outcomes in this middle-aged US population. This
hypothesis can be further supported by recent and consistent
evidence suggesting that the outcomes in critically ill patients
are improved by both tight glucose control and insulin therapy
with its anti-inflammatory properties [32-34].
This study has several limitations. First, the accuracy of ICD-9-
CM (the clinical modification of ICD-9) coding in identifying
specific medical conditions is unproven [35], yet it is increas-
ingly used for epidemiologic purposes [20]. In critical illness,
the sensitivity and specificity of the diagnostic code for sepsis
were estimated to be 87.7% and 98.8%, respectively. How-
ever, the use of ICD-9 codes for epidemiologic estimates may
underestimate true incidence [36].
Second, we have focused on patients who were hospitalized
and developed acute organ dysfunction, although we
acknowledge that definitions in critical care population are not
well validated. For example, some patients who had chronic
organ failure might have been captured with our definition, and
others might have developed organ failure and died without
being hospitalized.
Third, we did not subcategorize patients who were morbidly
obese (BMI > 40) because of the small sample size (about
3%). At the time of the study, morbid obesity was not as sig-
nificant problem as it has become over the past 15 years. It
seems that increased mortality and increased risk of multiple
complications in a morbidly obese population are more obvi-
ous, as shown in several retrospective studies, and should
therefore be studied separately [14,17,18,37].
Fourth, patients were enrolled in this trial in 1986 to 1989, and
both treatment for diabetes and treatment of acute organ fail-
ure may have changed in the years since then. However, it is
noteworthy that is that in the USA the proportion of diabetic
Figure 1
Time to development of acute organ failure among study participants Time to development of acute organ failure among study participants. 
The results are stratified by body mass index (a) and diabetes mellitus 
(b). From the Atherosclerosis Risk in Communities study 1986–1989 
and follow-up.Critical Care    Vol 10 No 5    Slynkova et al.
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patients who are 'well controlled', on the basis of hemoglobin
A1C levels, has not improved over the past two decades [38].
Fifth, our definition of DM might not have included all subjects
with this disease, in that we did not perform glucose tolerance
testing or other confirmatory testing. However, this potential
misclassification would have biased our results towards not
finding an effect in the DM population.
Finally, we included only three years of follow-up in this analy-
sis. This was done to focus on the short-term risk of BMI and
DM on acute organ failure. Over the long term, patients with
high BMIs are more likely to develop DM and would in all like-
lihood have an increased risk of acute organ failure and critical
illness subsequently.
Conclusion
Results of this study indicate that the presence of DM, rather
than an increased BMI, accounts for a higher risk of acute
organ failure and associated mortality. These findings call for
further investigation to determine the mechanisms that under-
lie this complex relationship between obesity, diabetes, and
critical illness. It will help to optimize care, which will result in
improved outcomes and a decrease in the associated health
care costs currently being expended in this growing popula-
tion of patients.
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